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Diffuse large B cell lymphoma (DLBCL) is a clinically and
molecularly heterogeneous disease.1 The majority of patients
respond to immunochemotherapy, generally consisting of ritux-
imab in combination with CHOP (cyclophosphamide, doxorubicin,
vincristine, prednisone) and 60–70% can be cured. Approximately
30% will develop a relapse, of which relapses in the central
nervous system (CNS), although relatively rare (~1%), carry a
particularly poor prognosis.2,3 The factors that determine homing
to extranodal sites such as the CNS are largely unknown, but a
much higher incidence of CNS relapse is observed in very
aggressive lymphoma types such as Burkitt lymphoma, lympho-
blastic lymphoma, and primary testicular lymphoma (PTL).
We and others have previously demonstrated that primary CNS
lymphomas (PCNSLs) and PTLs, both arising at immune-privileged
sites, are characterized by a high frequency of oncogenic
mutations in both CD79B, causing chronic active B cell receptor
(BCR) signaling, and in MYD88, an adapter protein that mediates
toll-like receptor (TLR) and interleukin-1 receptor signaling.4–7
Both mutations ultimately lead to activation of the NF-kB
pathway.8,9 Although they are found almost exclusively in
activated B cell type (ABC-type) DLBCL, there is a striking
difference in the prevalance of MYD88 mutations in PCNSL
(75%) and PTLs (71%) versus nodal lymphomas (17%) and
gastrointestinal (11%) lymphomas.6
To explore whether MYD88 and CD79B mutations are preferen-
tially associated with DLBCL originating in the CNS or testis, or
whether they are also present in DLBCL relapsing in the CNS, we
tested a panel of 14 patients with CNS relapse of a DLBCL. These
patients, with either leptomeningeal and/or brain parenchyma-
tous relapse, were treated in the phase II HOVON 80 NHL trial with
reinduction chemotherapy (consisting of three cycles of R-DHAP-
MTX (dexamethasone 40mg on days 1–4, cisplatin 100mg/m2 on
day 1, cytarabine 2 × 2 g/m2 on day 2, rituximab 375mg/m2
on day 5, methotrexate 3 g/m2 on day 15) and intrathecal
rituximab (registered at www.trialregister.nl as NTR1757, EudraCT
number 2006-002141-37). Patients with either a partial or a
complete response received consolidation with busulfan/cyclo-
phosphamide and autologous stem cell transplantation; all others
went off protocol. A total of 36 eligible patients, aged 23–65 years
(median 57 years) were treated between 2007 and 2011, 24 of
whom had parenchymal localizations on MRI and 18 of whom had
a leptomeningeal relapse. The overall response rate for these
patients was 53% (28% of patients reached a complete response),
with a median response duration of 6 months.10 Mutation analysis
was performed in the 14 patients for whom either brain biopsy
material or tumor-positive cerebrospinal ﬂuid (on the basis of
pathology and/or immunophenotyping results) was available. For
13 of these patients the biopsy material obtained at primary
diagnosis could also be retrieved.
We used a panel of allele-speciﬁc PCRs covering all major
mutation (hot) spots to detect somatic mutations in MYD88 and
CD79B. As recently reported, this strategy permits efﬁcient and
sensitive detection of mutations.6,7 The detected mutations were
veriﬁed by Sanger sequencing.
None of the 27 tested samples (13 primary material, 14 relapse
material) showed CD79B mutations and a MYD88 mutation was
found in 3/14 CNS relapse patients only (21%; Table 1).
Table 1. Clinical characteristics of DLBCL relapsing in the CNS and results of MYD88 and CD79b PCR
Patient Year of primary
lymphoma
diagnosis
Localization of
biopsy
Year of
CNS
relapse
Age at
CNS
relapse
Sex Parenchymal, CSF
or other CNS site of
relapse
MYD88
primary
localization
MYD88
relapse
brain/CSF
CD79B
primary
CD79B
relapse
If CSF,
clonal
BCR in
CSF?
001 2005 Bone 2007 64 F Brain − − − − n.a.
002 2006 Lung 2007 62 F Brain/CSF − − /− − − /− +
003 2003 Testis 2008 58 M Brain + + − − n.a.
004 2002 LN 2009 58 F Brain n.d. − − − n.a.
005 2009 Bone 2009 56 M Brain − − − − n.a.
006 2009 LN 2009 58 M Brain − − − − n.a.
007 2009 BM 2009 47 M CSF − − − − +
008 2001 LPLa
2010 DLBCL
LN 2010 58 M Brachial nerve + (LN) + − − n.a.
009 2009 Liver 2010 57 M CSF − − − − +
010 2010 LN 2010 23 F Brain − − − − n.a.
011 2008 Nasal cavity 2010 56 F Brain − − − − n.a.
012 2004 Testis 2010 65 M Brain + + − − n.a.
013 2010 LN 2011 63 F CSF − − − − +
014 2010 Breast 2011 45 F CSF − − − − +
Abbreviations: BCR, B cell receptor; CNS, central nervous system; CSF, cerebrospinal ﬂuid; DLBCL, diffuse large B cell lymphoma; LN, lymph node; n.a., not
applicable; n.d., not done. aPatient was diagnosed with lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (IgM Mprotein present) in 2001
and with nodal transformation to DLBCL in 2010, with subsequent neurological symptoms, brain parenchymal lesions and a lesion in the brachial nerve. The
brachial nerve biopsy was positive for DLBCL.
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Remarkably, of the three samples containing a MYD88 mutation,
two patients were originally diagnosed with PTL, whereas the third
patient had previously been diagnosed with a lymphoplasmacytic
lymphoma (LPL), with subsequent transformation to a (nodal)
DLBCL. In all the three positive cases a leucine-to-proline exchange
at position 265 (L265P) was demonstrated, the most frequently
found ‘hotspot’ mutation in both DLBCL and Waldenstrom’s
macroglobulinemia.11 In all three cases the primary material also
carried the mutation. Of the 11 DLBCL not originating from either
PTL or LPL none displayed a MYD88 mutation.
We have previously demonstrated that MYD88 mutations are
highly prevalent in both PCNSL and PTLs, but not in lymphomas
originating in ‘professional’ lymphoid organs/tissues such as the
lymph nodes or the Peyer’s patches in the gastrointestinal tract.
Frequently, in these tumors a CD79B mutation could also be
found.6,7 These ﬁndings support the concept that IP-DLBCLs
present a pathogenetically distinct group of lymphomas and we
propose that mutational activation of TLR/MYD88-signaling
endows lymphoma-initiating cells with a selective growth
advantage at immune-privileged sites. These tissues are barrier-
protected and immunologically silent and, in marked contrast to
lymph nodes and mucosa-associated lymphoid tissues, will
presumably provide only limited stimulation by TLR ligands. The
(concomitant) presence of CD79B (or other BCR-pathway) muta-
tions, causing chronic active BCR signaling, may further promote
the selective outgrowth of the tumor cells within these relatively
stimulus-poor microenvironments. Our current ﬁnding that DLBCL
relapsing in the CNS lack these mutations (unless the primary
lymphoma was either a PTL or an LPL) supports the hypothesis
that these molecular alterations are instrumental for tumor
initiation at immune-privileged sites but not for homing of
lymphoma cells to the CNS. Mechanisms guiding the latter
process remain to be unraveled.
In conclusion, previous studies by us and others indicate that
MYD88 mutations, and to a lesser extent CD79B mutations, are
important drivers of lymphomagenesis in PCNSL and PTL, but our
current results imply that these mutations do not play a role in
lymphomas relapsing in the CNS. This may have important
therapeutic consequences, as the patients with tumors containing
MYD88 and/or CD79mutations will more likely beneﬁt from therapies
targeting MYD88-signaling components like the IRAK kinase
inhibitors, either alone or in combination with drugs blocking key
mediators of BCR signaling such as Bruton’s tyrosine kinase.12,13
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